<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11720455</article-id><article-id pub-id-type="pmc">2375253</article-id><article-id pub-id-type="pii">6692069</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2069</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cottu</surname><given-names>P H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Extra</surname><given-names>J M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Espie</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marolleau</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roquancourt</surname><given-names>A de</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Makke</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Miclea</surname><given-names>J M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Laurence</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mayeur</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lerebours</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cuvier</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, H&#x000f4;pital Saint-Louis, 1 av Claude Vellefaux, Paris, 75010, France</aff><aff id="aff2"><label>2</label>Department of Cell Therapy, H&#x000f4;pital Saint-Louis, 1 av Claude Vellefaux, Paris, 75010, France</aff><aff id="aff3"><label>3</label>Department of Pathology, H&#x000f4;pital Saint-Louis, 1 av Claude Vellefaux, Paris, 75010, France</aff><aff id="aff4"><label>4</label>Department of Medical Oncology, H&#x000f4;pital Andr&#x000e9; Mignot, Le Chesnay, 78000, France</aff><pub-date pub-type="epub"><day>01</day><month>09</month><year>2001</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2001</year></pub-date><volume>85</volume><issue>9</issue><fpage>1240</fpage><lpage>1246</lpage><history><date date-type="received"><day>20</day><month>11</month><year>2000</year></date><date date-type="rev-recd"><day>10</day><month>07</month><year>2001</year></date><date date-type="accepted"><day>20</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The aim of this study was to evaluate the feasibility of a high-dose intensity and high-dose density multicycle epirubicin and cyclophosphamide regimen with peripheral blood stem cells (PBSC) and haematopoietic growth factor (G-CSF) support in advanced breast cancer patients. From August 1994 to September 1999, 56 breast cancer patients (8 stage IIIB and 48 stage IV) received 205 courses of cyclophosphamide 3&#x02008;g m<sup>&#x02212;2</sup>and epirubicin 100&#x02008;mg m<sup>&#x02212;2</sup>every 14 days. G-CSF 5&#x02008;&#x003bc;g kg<sup>&#x02212;1</sup>day<sup>&#x02212;1</sup>was administered from day 3 to neutrophil recovery. 4 courses were planned. PBSC were collected after course 1, and reinfused after courses 3 and 4, with &#x02265; 2 &#x000d7; 10<sup>6</sup>CD34+ PBSC kg<sup>&#x02212;1</sup>required for each reinfusion. 48 patients (86&#x00025;) received all 4 planned courses. Early withdrawal was consecutive to infectious complications (<italic>n</italic>= 4), severe asthenia (<italic>n</italic>= 3), haemorrhagic cystitis (<italic>n</italic>= 1). A median number of 10.8 &#x000d7; 10<sup>6</sup>CD34+ PBSC kg<sup>&#x02212;1</sup>(range, 3&#x02013;80) was harvested with 1 or 2 apheresis in 48 patients (94&#x00025;). Median relative dose intensity was 91.3&#x00025; (range, 72&#x02013;102&#x00025;). Grade 4 neutrophil toxicity was observed in 100&#x00025; of patients. Febrile neutropenia was observed in 40&#x00025; of courses (median duration 2 days). Red blood cells and platelets had to be transfused in 54&#x00025; and 27&#x00025; of courses, respectively. There were no toxic deaths. Objective response rate was 69&#x00025; in stage IV patients (31/45 evaluable pts), with a 16&#x00025; complete response rate. Their median progression-free and overall survivals were 22.5 and 37 months, respectively. This epirubicine-containing high-dose regimen appeared feasible, albeit with high toxicity. Time-related progression parameters exceed commonly reported ones. Controlled studies of upfront sequential high-dose chemotherapy are still needed to evaluate its real benefit. &#x000a9; 2001 Cancer Research Campaign</p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>advanced</kwd><kwd>chemotherapy</kwd><kwd>high-dose</kwd></kwd-group></article-meta></front></article>


